Hematologic Malignancy
Acute Myeloid Leukemia
CI-CAN-00001674AML · ANLLExplore in graph →
Hematologic789 active trials18 approved drugs279 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001674AML · ANLLExplore in graph →
Clinical trials
2,964 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (536)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02598752 | Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell Transplantation | completed | — | 11 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 16, 2020 | clinicaltrials |
| NCT01830777 | Brentuximab Vedotin + Re-induction Chemotherapy for AML | completed | Phase 1 | 22 | Massachusetts General HospitalOTHER | 1 | Apr 14, 2020 | clinicaltrials |
| NCT02573363 | Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia | completed | Phase 1 | 25 | University of ChicagoOTHER | 1 | Apr 8, 2020 | clinicaltrials |
| NCT02319135 | Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia(FLUGAZA) | completed | Phase 3 | 289 | PETHEMA FoundationOTHER | 1 | Apr 6, 2020 | clinicaltrials |
| NCT02530476 | Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 31, 2020 | clinicaltrials |
| NCT03170895 | Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD | completed | Phase 2 | 5 | The University of Hong KongOTHER | 1 | Mar 30, 2020 | clinicaltrials |
| NCT03622541 | Using Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying FLT3-ITD | completed | Phase 2 | 46 | The University of Hong KongOTHER | 1 | Mar 30, 2020 | clinicaltrials |
| NCT02212561 | Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | 19 | St. Jude Children's Research HospitalOTHER | 1 | Mar 26, 2020 | clinicaltrials |
| NCT04321161 | Analysis of T Cell Metabolism in Relapsed AML Patients With DLIs and Bicanorm Treatment | completed | Early Phase 1 | 10 | University of FreiburgOTHER | 1 | Mar 25, 2020 | clinicaltrials |
| NCT02252107 | 10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1 | completed | Phase 2 | 46 | Radboud University Medical CenterOTHER | 2 | Mar 19, 2020 | clinicaltrials |
| NCT02921061 | Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS | completed | Phase 1 / Phase 2 | 28 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 17, 2020 | clinicaltrials |
| NCT02416908 | Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 40 | Washington University School of MedicineOTHER | 1 | Mar 13, 2020 | clinicaltrials |
| NCT02892318 | A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML) | completed | Phase 1 | 40 | Hoffmann-La RocheINDUSTRY | 1 | Mar 13, 2020 | clinicaltrials |
| NCT02316964 | Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 8 | Sumithira VasuOTHER | 1 | Mar 9, 2020 | clinicaltrials |
| NCT02870777 | MRD-directed Therapy for Low-risk and Intermediate-risk AML. | completed | Phase 2 / Phase 3 | 743 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Mar 4, 2020 | clinicaltrials |
| NCT01546038 | A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 2 | 255 | PfizerINDUSTRY | 6 | Mar 3, 2020 | clinicaltrials |
| NCT01814826 | Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older | completed | Phase 1 | 64 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 3, 2020 | clinicaltrials |
| NCT02671708 | IDA+BUCY vs BUCY Conditioning Regimen for Intermediate-risk AML Undergoing Auto-HSCT | completed | Phase 2 / Phase 3 | 153 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Mar 3, 2020 | clinicaltrials |
| NCT01349049 | Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 90 | Daiichi SankyoINDUSTRY | 1 | Mar 2, 2020 | clinicaltrials |
| NCT03106428 | A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies | completed | Phase 1 | 67 | MedImmune LLCINDUSTRY | 3 | Feb 28, 2020 | clinicaltrials |
| NCT00783653 | Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 Years | completed | Phase 1 / Phase 2 | 22 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT00952588 | Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients(SPARK-AML1) | completed | Phase 2 / Phase 3 | 74 | AstraZenecaINDUSTRY | 9 | Feb 24, 2020 | clinicaltrials |
| NCT04259372 | Analysis of T Cell Metabolism in Acute Myeloid Leukemia Patients | completed | — | 77 | University of FreiburgOTHER | 0 | Feb 6, 2020 | clinicaltrials |
| NCT00068718 | Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant | completed | Phase 1 / Phase 2 | 35 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 31, 2020 | clinicaltrials |
| NCT00096161 | Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant | completed | Phase 2 | 36 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 31, 2020 | clinicaltrials |
| NCT00789776 | Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer | completed | Phase 1 / Phase 2 | 41 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 31, 2020 | clinicaltrials |
| NCT00040846 | Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies | completed | Phase 2 | 60 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 29, 2020 | clinicaltrials |
| NCT00045435 | Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission | completed | Phase 2 | 17 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 29, 2020 | clinicaltrials |
| NCT00453388 | Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia | completed | Phase 2 | 6 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 29, 2020 | clinicaltrials |
| NCT00342316 | Reduced Intensity Conditioning Transplantation Versus Standard of Care in Acute Myeloid Leukemia | completed | N/A | 340 | Vastra Gotaland RegionOTHER_GOV | 9 | Jan 27, 2020 | clinicaltrials |
| NCT02794207 | Home or Away From Home - Descriptive Interviews (Aim 2) | completed | — | 86 | Children's Hospital of PhiladelphiaOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT00006251 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | completed | Phase 1 / Phase 2 | 21 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 21, 2020 | clinicaltrials |
| NCT00014235 | Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies | completed | N/A | 160 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 21, 2020 | clinicaltrials |
| NCT00368355 | T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts(MOHEL) | completed | Phase 2 | 46 | Baylor College of MedicineOTHER | 1 | Jan 21, 2020 | clinicaltrials |
| NCT00078858 | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 18, 2020 | clinicaltrials |
| NCT00887068 | Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129) | completed | Phase 3 | 187 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT02044796 | Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | completed | Phase 1 / Phase 2 | 199 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 10, 2020 | clinicaltrials |
| NCT01664897 | Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 7, 2020 | clinicaltrials |
| NCT01527045 | Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies | completed | Phase 2 | 47 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT00723099 | Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer | completed | Phase 2 | 73 | Fred Hutchinson Cancer CenterOTHER | 1 | Dec 27, 2019 | clinicaltrials |
| NCT02774850 | Home Away From Home - Medical Outcomes(Aim 1) | completed | — | 610 | Children's Hospital of PhiladelphiaOTHER | 1 | Dec 23, 2019 | clinicaltrials |
| NCT02777021 | Home Away From Home - Quality of Life Surveys(Aim 3) | completed | — | 154 | Children's Hospital of PhiladelphiaOTHER | 1 | Dec 23, 2019 | clinicaltrials |
| NCT00027820 | Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | completed | Phase 1 / Phase 2 | 106 | Fred Hutchinson Cancer CenterOTHER | 3 | Dec 20, 2019 | clinicaltrials |
| NCT01629082 | Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia | completed | Phase 1 | 4 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT00013533 | Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies | completed | Early Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2019 | clinicaltrials |
| NCT00989261 | Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)(ACE) | completed | Phase 2 | 333 | Daiichi SankyoINDUSTRY | 9 | Dec 11, 2019 | clinicaltrials |
| NCT01300572 | Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS | completed | Phase 1 | 16 | Fred Hutchinson Cancer CenterOTHER | 1 | Dec 10, 2019 | clinicaltrials |
| NCT02017457 | Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation. | completed | Phase 2 | 50 | Carlos Graux, MD, PhDOTHER | 1 | Dec 10, 2019 | clinicaltrials |
| NCT01251575 | Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant | completed | Phase 2 | 77 | Fred Hutchinson Cancer CenterOTHER | 2 | Dec 9, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Apr 16, 2020source: clinicaltrials